Private equity firms eye $3B deal for vaccine maker Bavarian Nordicnews2025-07-28T12:29:08+00:00July 28th, 2025|Endpoints News|
GSK sends $500M upfront to Hengrui in broad deal with China’s leading pharmanews2025-07-28T08:41:25+00:00July 28th, 2025|Endpoints News|
Vaccine maker Bavarian Nordic confirms it’s in potential takeover talksnews2025-07-24T16:37:26+00:00July 24th, 2025|Endpoints News|
Novartis inks deal with covalent medicines biotech Matchpoint for $60M upfrontnews2025-07-24T14:34:47+00:00July 24th, 2025|Endpoints News|
Still in flux, Galapagos hires new execs, adjusts deal with Gilead, and considers selling its cell therapy businessnews2025-07-23T23:47:06+00:00July 23rd, 2025|Endpoints News|
Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfrontnews2025-07-22T05:30:33+00:00July 22nd, 2025|Endpoints News|
Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfrontnews2025-07-16T10:50:00+00:00July 16th, 2025|Endpoints News|
Merck’s partner LaNova Medicines is acquired for $951M by Sino Biopharmaceuticalnews2025-07-15T15:04:54+00:00July 15th, 2025|Endpoints News|
Anne Wojcicki’s nonprofit completes acquisition of 23andMe assetsnews2025-07-14T16:05:07+00:00July 14th, 2025|Endpoints News|
Varda raises $187M to advance drug manufacturing in spacenews2025-07-10T17:57:00+00:00July 10th, 2025|Endpoints News|
